ATE196314T1 - Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit - Google Patents

Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit

Info

Publication number
ATE196314T1
ATE196314T1 AT97946405T AT97946405T ATE196314T1 AT E196314 T1 ATE196314 T1 AT E196314T1 AT 97946405 T AT97946405 T AT 97946405T AT 97946405 T AT97946405 T AT 97946405T AT E196314 T1 ATE196314 T1 AT E196314T1
Authority
AT
Austria
Prior art keywords
compositions
methods
angiogenesis
alpha subunit
preventing inflammation
Prior art date
Application number
AT97946405T
Other languages
English (en)
Inventor
Kathleen Kelly
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE196314T1 publication Critical patent/ATE196314T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97946405T 1996-10-25 1997-10-24 Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit ATE196314T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2787196P 1996-10-25 1996-10-25
PCT/US1997/019772 WO1998017796A2 (en) 1996-10-25 1997-10-24 Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian cd97 alpha subunit

Publications (1)

Publication Number Publication Date
ATE196314T1 true ATE196314T1 (de) 2000-09-15

Family

ID=21840250

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97946405T ATE196314T1 (de) 1996-10-25 1997-10-24 Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit

Country Status (8)

Country Link
US (2) US6365712B1 (de)
EP (1) EP0938557B1 (de)
JP (1) JP2001510987A (de)
AT (1) ATE196314T1 (de)
AU (1) AU5158098A (de)
CA (1) CA2270154A1 (de)
DE (1) DE69703121D1 (de)
WO (1) WO1998017796A2 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU768859B2 (en) * 1999-07-29 2004-01-08 Dyax Corp. Binding moieties for fibrin
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US9364565B2 (en) * 2000-03-15 2016-06-14 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods of using same
CA2400319C (en) 2000-03-15 2008-09-16 Orbus Medical Technologies Inc. Coating that promotes endothelial cell adherence
US8460367B2 (en) * 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20030229393A1 (en) * 2001-03-15 2003-12-11 Kutryk Michael J. B. Medical device with coating that promotes cell adherence and differentiation
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US20070055367A1 (en) * 2000-03-15 2007-03-08 Orbus Medical Technologies, Inc. Medical device with coating that promotes endothelial cell adherence and differentiation
GB0009181D0 (en) * 2000-04-13 2000-05-31 Isis Innovation Protein
GB2367822A (en) * 2000-06-19 2002-04-17 Smithkline Beecham Corp CD97 polypeptides
US6984373B2 (en) 2000-12-23 2006-01-10 Dyax Corp. Fibrin binding moieties useful as imaging agents
WO2002064093A2 (en) 2001-02-15 2002-08-22 King Pharmaceuticals, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US8722654B2 (en) 2001-03-02 2014-05-13 The Brigham And Women's Hospital, Inc. Lipoxin analogs as novel inhibitors of angiogenesis
EP1406698B1 (de) 2001-03-02 2008-10-29 The Brigham and Women's Hospital Lipoxin analoge als neue inhibitoren der angiogenese
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
WO2003062438A1 (en) * 2002-01-22 2003-07-31 Biomatera Inc. Method of drying biodegradable polymers
US7727718B2 (en) * 2005-01-04 2010-06-01 Molecular Research Center, Inc. Reagents for storage and preparation of samples for DNA analysis
EP1981338A2 (de) * 2006-01-13 2008-10-22 Advanced Bionutrition Corporation Produktionssystem mit kontinuierlicher sprühnebelaufnahme
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
WO2011102394A1 (ja) 2010-02-17 2011-08-25 日本たばこ産業株式会社 植物内容成分の調節因子、およびその利用
EA030220B1 (ru) 2013-06-28 2018-07-31 Эмджен Инк. Устойчивая жидкая композиция, содержащая amg-416 (этелкалцетид)
ES2939760T3 (es) 2014-03-15 2023-04-26 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico para antígenos
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
US12128069B2 (en) 2015-04-23 2024-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3331913A1 (de) 2015-08-07 2018-06-13 Novartis AG Behandlung von krebs mithilfe von chimären cd3-rezeptor-proteinen
PL3380620T3 (pl) 2015-11-23 2024-11-12 Novartis Ag Zoptymalizowane lentiwirusowe wektory transferowe i ich zastosowanie
CA3009709A1 (en) 2015-12-30 2017-07-06 Novartis Ag Immune effector cell therapies with enhanced efficacy
WO2017149515A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3432924A1 (de) 2016-03-23 2019-01-30 Novartis AG Zellsekretierte minikörper und verwendungen davon
EP3443096B1 (de) 2016-04-15 2023-03-01 Novartis AG Zusammensetzungen und verfahren zur selektiven expression von chimären antigenrezeptoren
KR20190036551A (ko) 2016-08-01 2019-04-04 노파르티스 아게 Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
US11535662B2 (en) 2017-01-26 2022-12-27 Novartis Ag CD28 compositions and methods for chimeric antigen receptor therapy
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
KR20200086278A (ko) 2017-10-18 2020-07-16 노파르티스 아게 선택적 단백질 분해를 위한 조성물 및 방법
CN111566124A (zh) 2017-10-25 2020-08-21 诺华股份有限公司 制备表达嵌合抗原受体的细胞的方法
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
AU2020222345B2 (en) 2019-02-15 2022-11-17 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US12479817B2 (en) 2019-02-15 2025-11-25 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
CN110627903B (zh) * 2019-10-29 2021-09-21 河南大学 抗cd97单克隆抗体、其可变区与恒定区序列及应用
JP2023506958A (ja) 2019-12-20 2023-02-20 ノバルティス アーゲー 骨髄線維症および骨髄異形成症候群を処置するための、デシタビンまたは抗ｐｄ－１抗体スパルタリズマブを伴うかまたは伴わない抗ｔｉｍ－３抗体ｍｂｇ４５３および抗ｔｇｆ－ベータ抗体ｎｉｓ７９３の組合せ
AU2021288224A1 (en) 2020-06-11 2023-01-05 Novartis Ag ZBTB32 inhibitors and uses thereof
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
US20240384293A1 (en) 2021-04-27 2024-11-21 Novartis Ag Viral vector production system
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
AU2023369684A1 (en) 2022-10-26 2025-04-17 Novartis Ag Lentiviral formulations
AU2024276994A1 (en) 2023-05-24 2025-10-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2263219A1 (en) 1996-08-09 1998-02-19 Stichting Sanquin Bloedvoorziening Methods and means for modifying complement activation

Also Published As

Publication number Publication date
JP2001510987A (ja) 2001-08-07
EP0938557A2 (de) 1999-09-01
CA2270154A1 (en) 1998-04-30
AU5158098A (en) 1998-05-15
DE69703121D1 (de) 2000-10-19
US6365712B1 (en) 2002-04-02
EP0938557B1 (de) 2000-09-13
WO1998017796A2 (en) 1998-04-30
WO1998017796A3 (en) 1998-07-09
US20020168361A1 (en) 2002-11-14
US6846911B2 (en) 2005-01-25

Similar Documents

Publication Publication Date Title
ATE196314T1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
DE60039752D1 (de) Herstellung tetravalenter antikörper
TR200000913T2 (tr) Tıbbi maddeler
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
DE69841514D1 (de) Menschliche Toll-Like-Rezeptorproteine, zugehörige Reagenzien und Verfahren
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
TR200000015T2 (tr) Bileşikler ve metodlar
DE69900468D1 (de) Löslicher t-zell rezeptor
BR9707819A (pt) Imunogenos peptidicos
ATE337399T1 (de) Zusammensetzungen zur immuntherapie und diagnose von tuberculosis
HUP0401591A2 (hu) Új receptor-nukleinsavak és- polipeptidek
DK0845998T3 (da) Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
IL138424A0 (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
BG101024A (bg) Моноклонално антитяло срещу сd44v6
EE9900146A (et) Lahustuvad lümfotoksiin-ß retseptorid, lümfotoksiini retseptori vastased antikehad ja lümfotoksiini ligandi vastased antikehad terapeutiliste agensitena immunoloogiliste haiguste raviks
PE20010516A1 (es) Peptidos ciclicos con afinidad mejorada por los receptores de somatostatina
EP1762620A3 (de) Antigene aus Cryptosporidium parvum, Antikörper dagegen und diagnostische und therapeutische Zusammensetzungen
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
ATE316577T1 (de) Das goodpasture-antigen bindende protein
EA200001127A1 (ru) Бактериальные феромоны и их использование
DK1095143T3 (da) Inhibitor til diagnosticering og behandling af patienter med hæmofili A
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
DK0889907T3 (da) Monoklonale antistoffer, som binder humant væksthormon (hGH)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties